Melanoma News and Research

Latest Melanoma News and Research

Hybrid scanner helps to enhance visibility of skin cancer cells

Scientists are reporting development of a substance to enhance the visibility of skin cancer cells during scans with an advanced medical imaging system that combines ultrasound and light. The hybrid scanner could enable doctors to detect melanoma, the most serious form of skin cancer, in its earliest and most curable stages, the report in the monthly journal ACS Nano indicates.

12 Aug 2010

SMI/Omega development team receives fund to develop prototype fast multispectral endoscope

Cascade Technologies, Inc., announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will receive NIH research funding through a collaboration with Omega Optical of Brattleboro, Vermont. This effort will accelerate development of a new class of medical endoscopes enhanced with proprietary multispectral imaging technology. The principal investigators on the project are Dr. Gary Carver, Director of Research at Omega Optical, and Dr. Daniel L. Farkas, Chairman and CEO of SMI.

11 Aug 2010

Stoecker and Associates develops new software for early diagnosis of malignant melanoma

Detection of malignant melanoma, the most serious type of skin cancer, will soon be quicker and easier thanks to the work of researchers at Missouri University of Science and Technology.The research, which is funded by the National Institutes of Health, recently received a patent titled "Automatic Detection of Critical Dermoscopy Features for Malignant Melanoma Diagnosis." The patent applies to a method for computer-aided analysis of photographs of skin lesions to detect the cancer. Melanoma can be cured if it is diagnosed early enough.

11 Aug 2010

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd - Cancer Research UK's commercialisation and development arm - today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

RNL BIO research identifies adult stem cell's ability to inhibit cancer

The leading biopharmaceutical company specialized in adult stem cell therapeutics, RNL BIO Co., Ltd, announced on July 27th that adult stem cell was identified to have cancer suppressive activity in a preclinical study.

10 Aug 2010

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical University of South Carolina (MUSC).

9 Aug 2010

New research on use of medicine, diet to prevent UV-induced skin cancer

In most cases, non-melanoma skin cancers are caused by overexposure to ultraviolet radiation - the invisible rays from the sun that can burn the skin. To reduce the risk of skin cancer, dermatologists encourage the public to Be Sun Smart, including limiting sun exposure and using broad-spectrum sunscreens.

6 Aug 2010

New laboratory to speed up research for melanoma treatment set up at University of Bristol

A new Skin Cancer Research Fund Laboratory has been set up in Bristol to study cancer cells collected from skin cancer patients attending Frenchay Hospital. It is hoped the new facility will speed up research into treatments for malignant melanoma - the most deadly form of skin cancer. The new laboratory at the Microvascular Research Laboratories at the University of Bristol will be officially opened today (Tuesday August 22nd) by the director of the Skin Cancer Research Fund, Mr Paul Townsend.

6 Aug 2010

Melanoma risk rises with the use of sunbeds: Study

According to an Australian Melanoma Family study, use of sunbeds to get a tan can increase the risk of developing melanoma by 41 per cent. The study looked into the effects of sunbeds on 18-39-year-olds and found that 23 per cent of participants who had melanoma reported using these machines.

5 Aug 2010

Scientists suggest home genetic tests may cause unnecessary stress

In the age of the Internet, where cybercondriacs are just a mouse click away from a diagnosis, do-it-yourself home genetics test may seem like the next logical step in managing health. But these tests, which are relatively new and available online, are often not comprehensive and may cause unnecessary stress, warns Suzanne Mahon, DNSc., a clinical professor of hematology and oncology at Saint Louis University.

5 Aug 2010

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.

4 Aug 2010

Study solves puzzle behind different types of skin cancer on different body parts

A consistent all-over tan may be impossible to achieve because some body areas are much more resistant to tanning than others, a study has found.Researchers - funded by the Medical Research Council (MRC) - at the University of Edinburgh say the results explain why some holidaymakers find it so hard to achieve an even tan all over their body.

4 Aug 2010

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics, Inc. today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company's net loss declined to $3.8 million, or $0.04 per share, a $23.2 million improvement from the $27.0 million loss, or $0.39 per share, reported for the second quarter of 2009. The improvement resulted from higher revenues as well as reduced operating expenses.

4 Aug 2010

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.

3 Aug 2010

Patrys secures funding of up to A$15 million to support advancement of clinical products

Patrys Limited (ASX: PAB), a company focused on the development of natural human antibodies for the treatment of cancer, announced today that it has secured up to A$15 million in funding.

3 Aug 2010

OHSU acquires BSD-500 Hyperthermia System

BSD Medical Corporation is pleased to announce that Oregon Health & Science University has acquired a BSD-500 Hyperthermia System. OHSU is a leading university that provides world-class treatment for the most complex health care needs. OHSU has been ranked in U.S. News & World Report's annual rankings as one of America's Best Hospitals for 15 consecutive years and has been recognized in the medical specialties of cancer and endocrinology.

2 Aug 2010

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.

2 Aug 2010

Melanoma News and Research

Latest Melanoma News and Research

Hybrid scanner helps to enhance visibility of skin cancer cells

SMI/Omega development team receives fund to develop prototype fast multispectral endoscope

Stoecker and Associates develops new software for early diagnosis of malignant melanoma

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Synta second-quarter net loss increases to $9.1 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

RNL BIO research identifies adult stem cell's ability to inhibit cancer

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

New research on use of medicine, diet to prevent UV-induced skin cancer

New laboratory to speed up research for melanoma treatment set up at University of Bristol

Melanoma risk rises with the use of sunbeds: Study

Scientists suggest home genetic tests may cause unnecessary stress

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Study solves puzzle behind different types of skin cancer on different body parts

ZymoGenetics second-quarter net loss declines to $3.8 million

Vical second-quarter revenues decrease to $2.1 million

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

Patrys secures funding of up to A$15 million to support advancement of clinical products

OHSU acquires BSD-500 Hyperthermia System

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Melanoma News and Research

Latest Melanoma News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in